Litigation Details for BRISTOL-MYERS SQUIBB COMPANY v. XSPRAY PHARMA AB (D.N.J. 2022)
✉ Email this page to a colleague
BRISTOL-MYERS SQUIBB COMPANY v. XSPRAY PHARMA AB (D.N.J. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-02-23 |
| Court | District Court, D. New Jersey | Date Terminated | 2023-09-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Matthew J. Skahill |
| Patents | 7,491,725; 8,680,103 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BRISTOL-MYERS SQUIBB COMPANY v. XSPRAY PHARMA AB
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for BRISTOL-MYERS SQUIBB COMPANY v. XSPRAY PHARMA AB (D.N.J. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-05-09 | 88 | Opinion | 7,491,725 (“the ’725 Patent”), 8,680,103 (“the ’103 Patent”), and 8,242,270 (“the ’270 Patent”).…infringement of the ‘270 Patent in addition to the ‘725 Patent and the ‘103 Patents (the two Orange Book-listed…three patents asserted by BMS. [Amended Complaint ¶¶ 32 (the ’725 Patent), 44 (the ’103 Patent), 56 … of the patents asserted. [Amended Complaint ¶¶ 32 (the ’725 Patent), 44 (the ’103 Patent), 56 (the…drug will infringe the ’725 Patent, the ‘103 Patent, and the ‘270 Patent. At best, the record presently | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
